Amazon stock price: AMZN flat after-hours after Washington Supreme Court lawsuit ruling; $300 bull case stays

February 19, 2026
Amazon stock price: AMZN flat after-hours after Washington Supreme Court lawsuit ruling; $300 bull case stays

NEW YORK, Feb 19, 2026, 17:05 EST — After-hours

Amazon.com Inc (AMZN.O) held steady in after-hours trade Thursday, barely budging following a Washington Supreme Court decision allowing lawsuits tied to deaths involving sodium nitrite sold on its platform. Shares ticked up roughly 0.1% to $204.86. Plaintiffs’ attorney Carrie Goldberg argued Amazon “shouldn’t be profiting from products they know people use to harm themselves.” Amazon, for its part, pushed back, saying it disagreed with the ruling. Reuters

The ruling throws fresh headline risk onto Amazon just as the stock faces investor nerves, with debate swirling over whether the company’s giant $200 billion capital outlay planned for 2026 will deliver payback quickly enough. Analysts flagged that “the magnitude of the spend is materially greater than consensus expected.” The conversation has already spilled over to other cloud titans, namely Microsoft and Alphabet. Reuters

Wall Street was already treading carefully ahead of the court ruling. The S&P 500 closed off 0.28%, while the Nasdaq lost 0.31% Thursday as traders digested company outlooks and braced for crucial inflation numbers.

Washington’s high court tossed out the argument that suicide always severs the chain of causation in negligence cases, unanimously deciding to let the lawsuits move forward. The decision adds a fresh wrinkle to ongoing debates over whether courts can hold online platforms liable for third-party products sold through their sites.

Morgan Stanley’s Brian Nowak is sticking with his Overweight call and $300 target on Amazon, staying upbeat “through this uncertainty” while the company pours more into AI and builds out data-center capacity. He’s watching capex yield—how much extra revenue comes in for every dollar spent compared to last year—and sees room for that to pick up as AWS launches new data centers. Nowak highlighted “agentic commerce,” AI-driven shopping tools that buy on behalf of customers, and said he expects to see AMZN strike broad agentic partnerships down the line. Investing

Douglas J. Herrington, who heads Worldwide Amazon Stores, offloaded 4,784 shares on Feb. 17, according to a regulatory filing. The transaction took place under a Rule 10b5-1 plan, the pre-arranged program intended to sidestep insider trading concerns. As noted in the same filing, Herrington saw 11,959 restricted stock units vest two days prior. Post-sale, he directly owned 512,109 shares.

Even so, the risks are clear. Ongoing litigation that grows or results in expensive settlements would only tighten the squeeze on a retail operation already facing scrutiny. And if the AI push doesn’t translate into a clear pickup for AWS, investors could remain cautious about cash flow—and the mounting costs.

Next up: traders are zeroed in on Friday’s U.S. Personal Income and Outlays report, hitting at 8:30 a.m. ET. This one comes with the PCE price index, the inflation figure the Fed keeps front and center. Any unexpected move here can jolt rate expectations in a hurry and send high-spending megacap tech stocks like Amazon swinging.

Technology News Today

  • Seeing the invisible: WEHI joins ZEISS Labs@Location to power biomedical imaging
    April 15, 2026, 9:06 PM EDT. WEHI has become the first ZEISS Labs@Location partner in the Southern Hemisphere, linking Australia's biomedical institute to a global imaging network. The collaboration-nurtured for years by WEHI's Senior Research Scientist (Technology), Dr Niall Geoghegan-brings next-generation imaging technologies to Australia and ensures access to advanced tools for tackling pressing questions in medicine. The partnership underscores WEHI's world-class capability and its steady record of innovation and dedication. Officials say the alliance accelerates discovery by enabling researchers to visualize biological processes with greater clarity, supporting translational research and patient-impact outcomes. The move highlights ZEISS's commitment to scientific leadership and WEHI's growing role at the cutting edge of biomedical imaging.